A SECRET WEAPON FOR HEMGENIX

Variety of qualified individuals: CDEC discussed the uncertainty in the volume of sufferers with moderately significant to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who are classified as having moderate or average disorder could possibly have